7 Intriguing Healthcare Growth Stocks in the S&P 500: Part 2
|
|
- Matilda Hutchinson
- 6 years ago
- Views:
Transcription
1 7 Intriguing Healthcare Growth Stocks in the S&P 500: Part 2 August 15, 2016 by Chuck Carnevale of F.A.S.T. Graphs Introduction The S&P 500 index is commonly used as a benchmark that investors use to measure the performance of their individual portfolios against. However, the S&P 500 is comprised of a very diverse group of companies. Just about every classification of company you can imagine can be found in the S&P 500. Furthermore, it is also comprised of all of the major industry sectors. With this series of articles, I have been examining the S&P 500 constituents in the healthcare sector. In part 1, I presented what I consider to be attractively valued dividend growth stocks in the S&P 500 healthcare sector. In this part 2, I will continue to examine S&P 500 healthcare stocks; however, with this article I will focus on fairly valued non-dividend paying growth-oriented S&P 500 healthcare constituents. Passive versus Active Investing Choosing passive versus active stock portfolios is one of the most hotly debated subjects regarding investing in stocks. Passive investing implies investing in an index fund while active investing means carefully handpicking specific stocks that meet your own goals, objectives and risk tolerances. Personally, I have always preferred what Wall Street calls active investing. However, I take exception with that designation. My personal investment philosophy is to invest in attractively valued businesses with the objective of holding for the long-term. Consequently, my investment process could hardly be called active because there is little turnover in my portfolios. Therefore, I reject the designations active versus passive in favor of selective versus non-selective. It is my preference to carefully select my investments based on sound valuation and sound fundamental attributes. And more importantly, I prefer to select my investments based on their precise characteristics that meet my specific goals, objectives and risk tolerances. For example, my current personal investment objectives are to seek fairly valued high-quality dividend growth stocks with a history of increasing their dividends each year. Therefore, my goal is not simply maximum current income; I am also keenly focused on constructing a portfolio with the opportunity for that income to grow each year. In this regard, I consider long-term capital gain a secondary objective. To be clear, I do expect to generate a reasonable level of capital gains with my dividend growth stocks. Page 1, 2018 Advisor Perspectives, Inc. All rights reserved.
2 Investing in them when they are attractively valued gives me confidence that I can generate capital appreciation commensurate with each company s earnings growth. However, I am not concerned with outperforming the market on a total return basis, but I am concerned with outperforming the market on a total dividend income basis over the long term. This leads me to pointing out additional reasons why I reject passive - also known as index investing. For example, the S&P 500 is often used by investors as the primary benchmark to judge their performance against. However, that judgment is always based on total return calculations. I also often utilize the S&P 500 as a benchmark to judge my own portfolio against. However, relative to my current income oriented investment philosophy, my measurement for performance is based on how much dividend income my portfolio generates versus the S&P 500. Moreover, I also measure how fast that dividend income is growing compared to the S&P 500. In this dividend income regard, the S&P 500 is at a great disadvantage. I took a rough count and found that approximately 85 of the S&P 500 companies pay no dividends at all, and another 58 yield 1% or less. Using round numbers, more than 25% of the S&P 500 constituents offer none or very little in the way of dividends. Since my objective is a growing dividend income stream, I see no logical reason to own the index when so many of the constituents do not meet my specific objectives. Additionally, there are many S&P 500 constituents that I would never invest in on my own volition. Therefore, I see no reason why I would want to invest in them by purchasing the index when I would never invest in them by my own selection process. Moreover, my recent examination of the S&P 500 index constituents also discovered that the majority of the blue-chip dividend growth companies I would typically be attracted to are currently overvalued. Once again, if I am not willing to invest in them today because they are overvalued, therefore, I would not want to invest in them today via the index. However, with all that said, I also recognize and accept the reality that not everyone has the same investment objectives as I do. There are many prudent strategies that investors can choose to employ and there are many different kinds of individual stocks that can be selected for common stock portfolios. To me, the key is to clearly identify your personal objectives and risk tolerances, and then choose appropriate investments that are compatible with those goals. Investing is not a one-size-fits-all process. Attractive Healthcare Growth Stocks in the S&P 500 for the Total Return Investor Therefore, even though I personally favor dividend growth stocks, there are also valid reasons and return opportunities available through investing in non-dividend paying but growing companies. As I pointed out in part 1 of this series I have recently been examining the healthcare sector of the S&P 500 looking for attractively valued stocks. Consequently, in addition to the fairly valued dividend growth stocks I reported on in part 1, I also came across a few intriguing growth stock opportunities in the healthcare sector of the S&P 500. As a result, I felt compelled to share these findings with those who are interested in investing for growth or total return. The following Portfolio Review via FAST Graphs lists the seven S&P 500 healthcare growth stock constituents that I felt were worth taking a closer look at. There are various Page 2, 2018 Advisor Perspectives, Inc. All rights reserved.
3 reasons why I chose to highlight these specific examples. In all cases, I felt that valuations were fair, and in a few cases - even compelling. On the other hand, for the few that I found compelling, there are reasons why valuations are so low. Consequently, I highly recommend conducting your own thorough due diligence and research. Nevertheless, as an old associate of mine used to like to say, the problems appear to be already in the price. Therefore, I will provide a brief commentary on each selection indicating why I chose to feature it in this article. Allergan plc (AGN) Allergan PLC is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and distributing generic, brand and biosimilar products. I was attracted to Allergan based on its high and relatively consistent earnings growth since However, I was also struck by the fact that the market has valued Allergan s high earnings growth achievements at a market (average) valuation. I find this interesting, because it is very rare to find a company with such a high rate of earnings growth available at such a reasonable valuation. As evidenced by the blue normal P/E ratio line on the graph, the market has recently valued this stock at a 16 P/E ratio more or less. To me, that is a low valuation for a company that has grown earnings at 29% per annum. I was further intrigued by Allergan when I examined the company s cash flow and free cash flow per share. Both of these metrics suggest that the business is quite healthy on an operating basis. Judging by its historical earnings growth rate, I was not surprised to see that the consensus estimates of analysts expect this company to continue growing at mid-double-digit rates. I was also not surprised to see that expected earnings growth was lower than historical norms considering the company s already approaching a $100 billion market-cap. When I first examined gross and net profit margin, I was shocked to see that net margins virtually disappeared from 2012 through However, there were legitimate reasons why this happened, to include acquisition costs, failed mergers and other theoretically nonrecurring events. Page 3, 2018 Advisor Perspectives, Inc. All rights reserved.
4 As a result, when I looked at diluted earnings (GAAP) I saw a completely different perspective compared to what I saw when I looked at operating earnings and cash flows. Although I always like to examine GAAP results, I differ from many people regarding their importance or relevance as a valuation tool. When valuing a stock for potential investment, I am more concerned with how the business is performing as an operating company. Nevertheless, I felt it was important to point these issues out on this research candidate. Endo International plc (ENDP) Endo International PLC is a specialty healthcare company. The Company is engaged in developing, manufacturing, marketing and distribution of branded pharmaceutical and generic products as well as medical devices. What struck me about Endo International was its extremely low valuation. Earnings have clearly flattened in recent years, but I believe the stock price reaction seems way overdone. Consequently, I included this research candidate as a compelling valuation and potential recovery candidate. Therefore, I was not surprised to see the stock surge yesterday based on an impressive second-quarter earnings report. Nevertheless, I offer this as an interesting speculation based on compelling low valuation. However, as I looked deeper into additional important fundamental metrics, the speculative nature of this particular research candidate is important to note. Express Scripts Holding (ESRX) Express Scripts Holding Co offers healthcare management & administration services such as managed care organizations, health insurers, workers' compensation plans & government health programs. To me, there was very little not to like about Express Scripts and its consistently strong earnings growth rate history. But what I liked most was its compelling valuation. As I indicated earlier, it s hard to find a company with this type of earnings growth record trading at such a low valuation. Page 4, 2018 Advisor Perspectives, Inc. All rights reserved.
5 HCA Holdings Inc (HCA) HCA Holdings Inc is a health care services company. It operates general acute care hospitals, psychiatric hospitals; and rehabilitation hospitals. It also operates freestanding surgery centers. I was attracted to HCA Holdings current valuation in light of the moderately high overvaluation that the stock traded at through the summer of The stock price correction since then has potentially created a buying opportunity. My one caveat is the company s high debt-to-capital ratio. However, the company does have strong cash flows, and I ve read reports where management is focused on improving their debt situation. Return on assets (ROA), Return on Invested Capital (ROI) Laboratory Corp of America (LH) Laboratory Corp of America Holdings is a healthcare diagnostics company. The Company along with its subsidiaries provides clinical laboratory services and end-to-end drug development support. Although I really like the consistent operating history that Laboratory Corp of America Holdings has produced, I do want to point out that I consider its valuation a little high. Consequently, I would suggest Page 5, 2018 Advisor Perspectives, Inc. All rights reserved.
6 looking for a better entry point. Nevertheless, I felt it was worthy of inclusion in this article in spite of its moderately high valuation. Mallinckrodt Public Limited (MNK) Mallinckrodt PLC along with its subsidiaries operates in a specialty biopharmaceutical and nuclear imaging business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and nuclear imaging agents. Mallinckrodt is offered as a speculative undervalued research candidate. The primary appeal here would be the potential for P/E ratio expansion back to the range. Mylan N.V. (MYL) Mylan NV along with its subsidiaries is a pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. I was attracted to Mylan because I consider the stock extremely undervalued and I like its long-term growth prospects. I believe that recent acquisitions have added to this company s appeal, and I suspect future acquisitions are likely going forward. All in all, I believe that Mylan looks like a significantly undervalued above-average growing investment opportunity. Page 6, 2018 Advisor Perspectives, Inc. All rights reserved.
7 Summary and Conclusions With this two-part series I looked at what appeared to be attractively valued stocks in the healthcare sector of the S&P 500. In part 1, I highlighted dividend growth stocks. In this part 2, I highlighted more growth oriented S&P 500 healthcare constituents. Although I do believe that finding attractive valuation today is difficult, I do believe there are attractive investments available for those who are willing to look beyond the valuation of overall market. If you enjoyed this article, scroll up and click on the "Follow" button next to my name to see updates on my future articles in your feed. Disclosure: Long ESRX Disclaimer: The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients. Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted. The information in this document is believed to be accurate, but under no circumstances should a person act upon the information contained within. We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation. F.A.S.T. Graphs Page 7, 2018 Advisor Perspectives, Inc. All rights reserved.
Celgene: A Primer on Growth Stock Value Investing (GARP): Part 2
Celgene: A Primer on Growth Stock Value Investing (GARP): Part 2 November 13, 2015 by Chuck Carnevale of F.A.S.T. Graphs Introduction This article is the second in a two-part series on applying the principles
More informationEmerson Electric: High-yield, Sound Valuation and 59 Consecutive Years of Dividend Increases, Part 2
Emerson Electric: High-yield, Sound Valuation and 59 Consecutive Years of Dividend Increases, Part 2 May 27, 2016 by Chuck Carnevale of F.A.S.T. Graphs Introduction When I m looking for a stock to add
More information10 Dividend Growth Stocks for Your Retirement Portfolios Aggregate Yield 4.3%: Part 2
10 Dividend Growth Stocks for Your Retirement Portfolios Aggregate Yield 4.3%: Part 2 August 12, 2015 by Chuck Carnevale of F.A.S.T. Graphs Introduction After an exhaustive search of the dividend growth
More informationDesigning a Retirement Portfolio That s Just Right For You
Designing a Retirement Portfolio That s Just Right For You July 10, 2015 by Chuck Carnevale of F.A.S.T. Graphs Introduction No one knows your own personal financial situation better than you do. Every
More informationj2 Global: Don t Overlook This Impressive Growth and Dividend Income Stock
j2 Global: Don t Overlook This Impressive Growth and Dividend Income Stock March 3, 2017 by Chuck Carnevale of F.A.S.T. Graphs j2 Global (JCOM) was founded in 1995 and went public in 1999. During their
More informationHow to Forecast Future Stock Returns: Part 3
How to Forecast Future Stock Returns: Part 3 Chuck Carnevale - Monday, July 16, 2012 Introduction In Part 1 and Part 2 of this three-part series, we established the basic principles of valuation and provided
More informationThe Great Beta Hoax: Not an Accurate Measure of Risk After All
The Great Beta Hoax: Not an Accurate Measure of Risk After All May 21, 2015 by Chuck Carnevale of F.A.S.T. Graphs Every investor is concerned with risk at some level. Arguably investors in retirement are
More informationDividends True Contribution to Total Return May Surprise You
Dividends True Contribution to Total Return May Surprise You March 30, 2016 by Chuck Carnevale of F.A.S.T. Graphs Introduction In recent years, dividends contribution to total return has been one of the
More informationWhich Is the Better Valuation Metric? The P/E Ratio or the PEG Ratio: Part 1
Which Is the Better Valuation Metric? The P/E Ratio or the PEG Ratio: Part 1 October 28, 2016 by Chuck Carnevale of F.A.S.T. Graphs Introduction Recently, I have been engaged in rather intense discussions
More informationCampbell Soup Company: High-Yield and Speculative Capital Gain Potential-Part 4
Campbell Soup Company: High-Yield and Speculative Capital Gain Potential-Part 4 June 7, 2018 by Chuck Carnevale of F.A.S.T. Graphs This is the fourth of what will be a long-running series highlighting
More informationThese Are the Only Dividend Aristocrats I Would Consider Today
These Are the Only Dividend Aristocrats I Would Consider Today July 8, 2016 by Chuck Carnevale of F.A.S.T. Graphs Generally speaking, the overall stock market is fully valued at best, and in many cases
More informationDesigning a Dividend Growth Portfolio for a Specific Retirement Yield Objective: Part 1
Designing a Dividend Growth Portfolio for a Specific Retirement Yield Objective: Part 1 October 2, 2015 by Chuck Carnevale of F.A.S.T. Graphs Introduction Managing an investment portfolio is a very personal
More information10 Attractive Dividend Growth Stocks Poised to Become the Next Dividend Champions Or Aristocrats
10 Attractive Dividend Growth Stocks Poised to Become the Next Dividend Champions Or Aristocrats January 12, 2016 by Chuck Carnevale of F.A.S.T. Graphs Introduction I screened the Dividend Contenders list
More informationIs The Increase In Volatility Signaling A Dangerous Market Environment?
Introduction Is The Increase In Volatility Signaling A Dangerous Market Environment? November 14, 2016 by Chuck Carnevale of F.A.S.T. Graphs Over the last several weeks stock price volatility has increased
More informationWhat Will Happen To the Stock Market When Interest Rates Rise? Part 1
What Will Happen To the Stock Market When Interest Rates Rise? Part 1 July 21, 2016 by Chuck Carnevale of F.A.S.T. Graphs Introduction Interest rates have been in a freefall for the better part of the
More information20 Dividend Growth Stocks To Buy Today For Your Retirement Portfolios: Part 1
20 Dividend Growth Stocks To Buy Today For Your Retirement Portfolios: Part 1 August 7, 2015 by Chuck Carnevale of F.A.S.T. Graphs Introduction We are in the seventh year of a strong bull market, and stock
More information5 Fairly Valued MLPs: Is the Dilution Worth the Yield and How Do You Value Them?
5 Fairly Valued MLPs: Is the Dilution Worth the Yield and How Do You Value Them? February 23, 2017 by Chuck Carnevale of F.A.S.T. Graphs Introduction The 5 MLPs covered in this article offer yields ranging
More informationThe Threat and Risk of Rising Interest Rates: Separating Fact from Fiction
The Threat and Risk of Rising Interest Rates: Separating Fact from Fiction March 24, 2017 by Chuck Carnevale of F.A.S.T. Graphs Introduction The threat of rising interest rates is all the rage in financial
More informationHope Is Not A Strategy, Before Investing Have A Precise Calculation Of Return In Mind
Hope Is Not A Strategy, Before Investing Have A Precise Calculation Of Return In Mind May 2, 2015 by Chuck Carnevale of F.A.S.T. Graphs Introduction Many people make the mistake of investing in a stock
More informationDividends Don t Drive Total Return They Contribute To It: Part 1
Dividends Don t Drive Total Return They Contribute To It: Part 1 March 3, 2016 by Chuck Carnevale of F.A.S.T. Graphs I believe there is a critical piece of investment wisdom that all investors in common
More information10 Undervalued Dividend Champions For 2016: Be Greedy When Others Are Fearful
10 Undervalued Dividend Champions For 2016: Be Greedy When Others Are Fearful December 24, 2015 by Chuck Carnevale of F.A.S.T. Graphs Introduction Dividend Champions/Aristocrats are the go-to dividend
More informationBlackRock Inc: Fundamental Stock Research Analysis
BlackRock Inc: Fundamental Stock Research Analysis May 9, 2013 by Team of F.A.S.T. Graphs Before analyzing a company for investment, it s important to have a perspective on how well the business has performed.
More informationDon t Be a Stock Market Victim!
Don t Be a Stock Market Victim! December 27, 2018 by Chuck Carnevale of F.A.S.T. Graphs Introduction The primary objective of this article is to help the reader put this recent bad market in perspective
More informationPeter Lynch Taught Me to Invest in Ultra Beauty Inc.
Introduction Peter Lynch Taught Me to Invest in Ultra Beauty Inc. February 1, 2018 by Chuck Carnevale of F.A.S.T. Graphs In his best-selling book One up on Wall Street Peter Lynch included this subtitle
More informationAmerican Eagle Outfitters Inc: Fundamental Stock Research Analysis
American Eagle Outfitters Inc: Fundamental Stock Research Analysis June 18, 2013 by Team of F.A.S.T. Graphs Before analyzing a company for investment, it s important to have a perspective on how well the
More informationArcher Daniels Midland Co: Fundamental Stock Research Analysis
Archer Daniels Midland Co: Fundamental Stock Research Analysis April 19, 2013 by Team of F.A.S.T. Graphs Before analyzing a company for investment, it s important to have a perspective on how well the
More informationU.S. Stocks: Can We Capture Acceptable Returns From Here?
March 2015 For discretionary use by investment professionals. U.S. Stocks: Can We Capture Acceptable Returns From Here? Editor s Note: The following commentary was written by Litman Gregory co founder
More informationDemo 3 - Forecasting Calculator with F.A.S.T. Graphs. Transcript for video located at:
Demo 3 - Forecasting Calculator with F.A.S.T. Graphs Transcript for video located at: http://www.youtube.com/watch?v=de29rsru9js This FAST Graphs, Demo Number 3, will look at the FAST Graphs forecasting
More informationFossil Inc Fundamental Stock Research Analysis
Fossil Inc Fundamental Stock Research Analysis January 22, 2013 by Team of F.A.S.T. Graphs Growth stocks are defined as companies with high rates of change of earnings growth of 15% to 20% or better. Growth
More informationDesigning the Appropriate Common Stock Retirement Portfolio: Stock Selection Options Part 1
Designing the Appropriate Common Stock Retirement Portfolio: Stock Selection Options Part 1 September 14, 2015 by Chuck Carnevale of F.A.S.T. Graphs Introduction What is the best way to design or construct
More informationWhen is the PEG Ratio Superior to the P/E Ratio? Part 2
When is the PEG Ratio Superior to the P/E Ratio? Part 2 November 3, 2016 by Chuck Carnevale of F.A.S.T. Graphs Introduction Financial metrics such as P/E ratios, price to cash flow ratios, PEG ratios,
More informationStock Selection Options by Category: Part 2A
Stock Selection Options by Category: Part 2A October 31, 2018 by Chuck Carnevale of F.A.S.T. Graphs Introduction In part 1 of this series titled How Many Stocks Should I Own? found here, I focused primarily
More informationVF Corp: Fundamental Stock Research Analysis
VF Corp: Fundamental Stock Research Analysis January 18, 2013 by Team of F.A.S.T. Graphs By FAST Graphs VF Corp: Fundamental Stock Research Analysis Before analyzing a company for investment, it s important
More informationFinding Great Value In The Energy Sector
Finding Great Value In The Energy Sector June 21, 2013 by Chuck Carnevale of F.A.S.T. Graphs This will be the second in a series of articles designed to find value in today s stock market environment.
More informationUser Guide for Schwab Equity Ratings Report
User Guide for Schwab Equity Ratings Report The Schwab Equity Ratings Report will help you make informed decisions on equities by providing you with important additional information and analysis. Each
More informationIn Today s Overheated Market Control Risk in Your Retirement Portfolios with Sound Valuation
In Today s Overheated Market Control Risk in Your Retirement Portfolios with Sound Valuation August 21, 2015 by Chuck Carnevale of F.A.S.T. Graphs Introduction Investing money in anything is never without
More informationDividends: A Timeless Component of Equity Return
Dividends: A Timeless Component of Equity Return May 15, 2012 by Loomis Sayles & Company, L.P. With interest rates at historic lows and many dividend-paying stocks boasting yields comparable to or higher
More informationBuilding Efficient Hedge Fund Portfolios August 2017
Building Efficient Hedge Fund Portfolios August 2017 Investors typically allocate assets to hedge funds to access return, risk and diversification characteristics they can t get from other investments.
More informationPart 3: Private Equity Strategies
Private Equity Education Series Part 3: Private Equity Strategies Reports in this series Report Highlights Page Part 1: What is Private Equity (PE)? Part 2: Investing in Private Equity Part 3: Private
More informationSEATTLE S BEST COFFEE? Using ZRS and the Zacks Valuation Model to identify factors impacting equity valuations in 3 minutes or less
Using ZRS and the Zacks Valuation Model to identify factors impacting equity valuations in 3 minutes or less SEATTLE S BEST COFFEE? Starbucks: Can this International coffeehouse add value to your portfolio?
More informationWhy Buy & Hold Is Dead
Why Buy & Hold Is Dead In this report, I will show you why I believe short-term trading can help you retire early, where the time honored buy and hold approach to investing in stocks has failed the general
More informationFirst Cut Stock Study Report
First Cut Stock Study Report Company Name: Biogen Inc. Ticker: BIIB Date of Study: 11/15/2016 (price date 11/14/2016) Price: 321.49 Your Name: Email address: Suzi Artzberger suzia@betterinvesting.org City:
More informationInvest In Walgreens Or CVS Speculate In Rite Aid
Invest In Walgreens Or CVS Speculate In Rite Aid January 23, 2018 by Chuck Carnevale of F.A.S.T. Graphs Introduction For many years now, investing in healthcare related stocks has presented me with a conundrum
More informationAI: Weighted Sector Strategy DEC
KEN STERN & ASSOCIATES DEC 31 2016 1 Tactical Rebalanced AI: Strategy DEC 31 2016 Ken Stern & Associates Strategy seeks to track the investment results of the Morgan Stanley Capital International USA Investable
More informationHealthcare and Life Sciences Private Debt and Royalty Opportunities
Healthcare and Life Sciences Private Debt and Royalty Opportunities Q1 2018 Please see last page for important disclosures. P a g e 2 The views expressed herein reflect the opinions of certain Marathon
More informationFranklin Select U.S. Equity Fund. Advisor Class
Franklin Select U.S. Equity Fund Advisor Class Blend Equity Product Profile Product Details 1 Fund Assets $91,842,807.55 Fund Inception Date 12/13/2007 Number of Issuers 49 NASDAQ Symbol FCEZX Maximum
More information1Q 2018 Market Insights Can a Few Bad Apples Spoil the Bunch? Ryan J. Lehman, CFA, CAIA
1Q 2018 Market Insights Can a Few Bad Apples Spoil the Bunch? Ryan J. Lehman, CFA, CAIA Speculative bubbles do not end like a short story, novel, or play. There is no final denouement that brings all the
More informationHedge Fund Indices and UCITS
Hedge Fund Indices and UCITS The Greenwich Hedge Fund Indices, published since 1995, fulfill the three basic criteria required to become UCITS III eligible. The Indices provide sufficient diversification,
More informationACTIVIST INVESTING RESEARCH
106 Yeakel Avenue Erdenheim, PA 19038 Damien J. Park President & CEO dpark@hedgerelations.com T: 215.325.0514 F: 215.392.4633 ACTIVIST INVESTING RESEARCH Company: Endo Pharmaceuticals Holdings, Inc. (ENDO)
More informationOramed Pharmaceuticals Inc. (ORMP $7.21*)
Oramed Pharmaceuticals Inc. (ORMP $7.21*) Healthcare: Specialty Pharmaceuticals Buy; $20.00 PT; $104.2M Market Cap Company Update Tuesday, April 17, 2018 Revenue/EPS for 2Q18 in Line/Beat Estimates; Time
More informationCelebrating Eight Years of Absolute Return How our Absolute Return portfolio has fared
For Financial Advisor Use Only Celebrating Eight Years of Absolute Return How our Absolute Return portfolio has fared Venus Phillips Investment Manager Morningstar Investment Services Morningstar Investment
More informationEquity Volatility and Covered Call Writing
December 2017 Equity Volatility and Covered Call Writing Executive Summary Amid uncertainty in the markets and investor desire for lower volatility, investors may want to consider a covered call strategy
More informationWhy Your Broker Won t Tell You About Covered Calls Introduction Welcome to our free report, "Covered Calls: What Your Broker Won t Tell You " Today, we re going to keep this report short and sweet but
More informationFocus on Funds As of December 31, 2009
Focus on Table Of Contents Page Review of the Markets........................................ 1 Money Market Fund.......................................... 2 Accumulative Income Fund.....................................
More informationSmall Cap Composite (Gross) 16.2% 16.2% 11.7% Top 0.0%
First Quarter 2013 Portfolio Review General It is difficult not to be pleased with the strong start to the year that we have enjoyed during the first quarter of 2013. Our results are particularly noteworthy
More informationHSBC USA Inc. Buffered Digital Notes Linked to the Dow Jones Industrial Average
Filed Pursuant to Rule 433 Registration No. 333-202524 September 1, 2016 FREE WRITING PROSPECTUS (To Prospectus dated March 5, 2015, Prospectus Supplement dated March 5, 2015 and Equity Index Underlying
More informationIs The Financial Crisis Over For Financial Stocks?
Is The Financial Crisis Over For Financial Stocks? August 8, 2013 by Chuck Carnevale of F.A.S.T. Graphs The cause of the financial crisis of 2007-2008, also known as the Great Recession of 2008, is attributed
More informationNote Important Disclosures on pages 4 and 5 Note Analyst Certification on page 4
COMPANY UPDATE / RATING CHANGE Key Metrics LDR - NYSE (as of 09/05/17) $61.35 Price Target N/A 52-Week Range $41.35 - $62.85 Shares Outstanding (mm) 9.6 Market Cap. ($mm) $591.3 Enterprise Value ($mm)
More informationIt s Déjà Vu All Over Again Yogi Berra
December 9, 2015 It s Déjà Vu All Over Again Yogi Berra In a client letter I penned on January 10, 1998, I wrote, As was the case in 1995 and 1996, large capitalization stocks (S&P 500) outperformed their
More informationCBRE U.S. Healthcare Capital Markets Group
CBRE U.S. Healthcare Capital Markets Group 2018 Healthcare Real Estate Investor & Developer Survey Results 2018 HEALTHCARE REAL ESTATE INVESTOR & DEVELOPER SURVEY RESULTS Dear Healthcare Real Estate Providers,
More informationRetired Investors: Apply a Value Investing Strategy and Earn More Income and Higher Returns
Retired Investors: Apply a Value Investing Strategy and Earn More Income and Higher Returns November 10, 2015 by Chuck Carnevale of F.A.S.T. Graphs Introduction Value investing produces safe, powerful
More informationFirst Trust AlphaDEX TM U.S. Health Care Sector Index ETF
First Trust AlphaDEX TM U.S. Health Care Sector Index ETF Interim June 30, 2015 INTERIM MANAGEMENT REPORT OF FUND PERFORMANCE June 30, 2015 (the First Trust ETF ) This interim management report of fund
More informationXPH SPDR S&P Pharmaceuticals ETF
SPDR S&P ETF ETF.com segment: Equity: U.S. Competing ETFs: IHE, PJP, FTXH Related ETF Channels: Sectors, Healthcare, Equal-Weighted, U.S., Smart-Beta ETFs, Equity, North America, Find more ETFs with our
More informationStocks 2014: Investing for Growth - The Power and Protection of High Compounding Earnings Growth
Stocks 2014: Investing for Growth - The Power and Protection of High Compounding Earnings Growth January 21, 2014 by Chuck Carnevale of F.A.S.T. Graphs As I become more mature (translate: gotten older),
More informationThe Value of Dividends. Searching for Income in a Low-Rate Environment. The Value of Dividends. Highlights. Long-Term Total Return Driver
The Value of Dividends The Value of Dividends Searching for Income in a Low-Rate Environment Matt Oldroyd, CFA, American Century Investments Vice President, Client Portfolio Manager, Value Equities Highlights
More informationDURSO WEALTH MANAGEMENT GROUP AT MORGAN STANLEY April 29, 2016 ECONOMIC LANDSCAPE
ECONOMIC LANDSCAPE The risk-on rotation that took hold in early February continued through the end of the first quarter and has spilled over to the month of April. What has changed? Global recession fears
More informationThrough their philanthropic efforts, foundations from Maine to
BRIEFING Investment Policy Statements for Non-Profit Organizations A Template for Prudent Investment Decisions We expect widespread revisions of investment policy statements that will result in more flexible
More informationNote Important Disclosures on Pages 5-6 Note Analyst Certification on Page 5.
COMPANY UPDATE / ESTIMATE CHANGE / PRICE TARGET CHANGE Key Metrics FUN - NYSE (as of 9/11/17) $64.67 Two Year Price Target $77.00 52-Week Range $56.23 - $72.56 Shares Outstanding (mil) (basic) 56.1 Market
More informationStock Market Expected Returns Page 2. Stock Market Returns Page 3. Investor Returns Page 13. Advisor Returns Page 15
Index Stock Market Expected Returns Page 2 Stock Market Returns Page 3 Investor Returns Page 13 Advisor Returns Page 15 Elections and the Stock Market Page 17 Expected Returns June 2017 Investor Education
More informationBaron WealthBuilder Fund
Dear builder Shareholder: The December quarter was a difficult one for equity markets. During the three-month period ended, markets experienced significant and highly correlated declines. This was in response
More informationThe Outlook For Emerging Markets Stocks
Page 1 of 5 Printed and electronic copies are for personal use. Any unauthorized distribution by fax, email or any other means is prohibited and is in violation of copyright. If you are interested in redistribution,
More informationThe Evolution of High-Yield Bonds into a Vital Asset Class
Allianz Global Investors White Paper Series The Evolution of High-Yield Bonds into a Vital Asset Class 07/2016 Executive Summary With high-quality bond yields near all-time lows, investors have looked
More informationExhibit 1. Availability of Public Information
Exhibit 1. Availability of Public Information In your view, how important do you think it is to have information about each of the following available to the public? Clinical quality health outcomes (e.g.,
More informationinvestment research policy
February 2018 investment research policy The purpose of this research policy is to ensure that retail investors understand the way in which we arrive at our view on an investment. This includes whether
More informationThe purpose of this paper is to briefly review some key tools used in the. The Basics of Performance Reporting An Investor s Guide
Briefing The Basics of Performance Reporting An Investor s Guide Performance reporting is a critical part of any investment program. Accurate, timely information can help investors better evaluate the
More informationActive vs. Passive Money Management
Active vs. Passive Money Management Exploring the costs and benefits of two alternative investment approaches By Baird s Advisory Services Research Synopsis Proponents of active and passive investment
More informationFranklin Equity Income Fund Advisor Class
Franklin Equity Income Fund Advisor Class Value Equity Product Profile Product Details 1 Fund Assets $2,255,651,608.76 Fund Inception Date 03/15/1988 Number of Issuers 69 NASDAQ Symbol FEIFX Maximum Sales
More informationBoston University Undergraduate Finance & Investment Club Investment Policy Statement
Boston University Undergraduate Finance & Investment Club Investment Policy Statement [Adapted from Scott D. Stewart s Training Student Equity Analysts and Utilizing their Recommendations in Active Portfolio
More informationThe Truth About Top-Performing Money Managers
The Truth About Top-Performing Money Managers Why investors should expect and accept periods of poor relative performance By Baird s Advisory Services Research Executive Summary It s only natural for investors
More informationAdverse Active Alpha SM Manager Ranking Model
CONSULTING GROUP INVESTMENT ADVISOR RESEARCH DECEMBER 3, 2013 Adverse Active Alpha SM Manager Ranking Model MATTHEW RIZZO Vice President Matthew.Rizzo@ms.com +1 302 888-4105 Introduction Investment professionals
More informationChapter 1: Investment versus Speculation: Results to be expected by the Intelligent Investor
Chapter 1: Investment versus Speculation: Results to be expected by the Intelligent Investor 1 Investment versus Speculation An investment operation is one which, upon thorough analysis promises safety
More informationActive vs. Passive Money Management
Active vs. Passive Money Management Exploring the costs and benefits of two alternative investment approaches By Baird s Advisory Services Research Synopsis Proponents of active and passive investment
More informationPSYCHEMEDICS CORP. (PMD)
DECEMBER 10, 2018 This article was written with David J. Flood from The Investor s Podcast Introduction Pychemedics Corporation is a U.S. based medical diagnostics & research company whose principal business
More informationPOLEN FOCUS GROWTH STRATEGY
PORTFOLIO MANAGER COMMENTARY Third Quarter 2017 POLEN FOCUS GROWTH STRATEGY Key Takeaways During the third quarter of 2017, the Polen Focus Growth Composite Portfolio (the Portfolio ) returned 4.04% gross
More informationWhy Do You Invest Money? Investment Choices The Winning Edge Definition Impact on Portfolio Value Impact on Risk...
Table of Contents Why Do You Invest Money?... 3 Investment Choices... 5 The Winning Edge... 6 Definition... 6 Impact on Portfolio Value... 6 Impact on Risk... 10 Conclusions... 14 Key Components... 14
More informationActive vs. Passive Money Management
Synopsis Active vs. Passive Money Management April 8, 2016 by Baird s Asset Manager Research of Robert W. Baird Proponents of active and passive investment management styles have made exhaustive and valid
More informationEPS = (Total Company Earnings) / (Shares Outstanding)
Basic Ratios Ratios are a common tool investors use to relate a stock's price with an element of the underlying company's performance. These quick and dirty ratios can be useful in their own way, as long
More informationHow Wealthy People Use Professional Money Management
How Wealthy People Use Professional Money Management Provided to you by: Tom Abboud CFEd Financial Planner How Wealthy People Use Professional Money Management 1 Written by Financial Educators Provided
More informationIntroducing. Manulife DrugWatch. Applying rigorous oversight to help ensure value for money in a dramatically changing drug market
Introducing Manulife DrugWatch Applying rigorous oversight to help ensure value for money in a dramatically changing drug market The drug market in Canada is changing rapidly and dramatically Many Canadians
More informationRisk averse. Patient.
Risk averse. Patient. Opportunistic. For discretionary use by investment professionals. Litman Gregory Portfolio Strategies at a Glance We employ tactical asset allocation by identifying undervalued asset
More informationCIBC WM INCOME TRUST BENCHMARK INDEX METHODOLOGY
CIBC WM INCOME TRUST BENCHMARK INDEX METHODOLOGY August 30, 2004 Yin Luo (416) 956-3291 yin.luo@cibc.ca Dawn Jia (416) 594-7136 dawn.jia@cibc.ca CIBC World Markets Inc. (CIBC WM) produces a family of 30
More informationLaura's Big Day [students] Page 1 of 5. Laura s big day
Laura's Big Day [students] Page 1 of 5 Laura s big day Laura Jones has just left school and got her first job with a local company. She s very excited at earning decent money at last and is looking forward
More informationHSBC USA Inc. Barrier Digital Return Notes Linked to the Least Performing of the Dow Jones Industrial Average and the Russell 2000 Index
Filed Pursuant to Rule 433 Registration No. 333-223208 July 26, 2018 FREE WRITING PROSPECTUS (To Prospectus dated February 26, 2018, Prospectus Supplement dated February 26, 2018 and Equity Index Underlying
More informationUsing ZRS and the Zacks Valuation. Model to identify factors impacting equity valuations in 3 minutes or less
Using ZRS and the Zacks Valuation Model to identify factors impacting equity valuations in 3 minutes or less FAMILY DOLLAR (FDO) Family Dollar: Is this Recessionary Outperformer Still an Attractive Stock?
More informationMutual Fund Research Process
Mutual Fund Research Process Identifying high-quality managers // Clearly defined process KEY TAKEAWAYS Raymond James believes that providing in-depth, unbiased research is an important tool for making
More informationClient Statement of Disclosure
Client Statement of Disclosure Updated as March 28, 2018 Sinclair-Cockburn Financial Services Inc. and our Relationship with You Sinclair-Cockburn Financial Services Inc. (hereinafter called SCFS) is both
More informationSTARBUCKS & WHOLE FOODS MARKET: S&P 500 Laggards of 2014 ON THE Rebound IN 2015?
Using ZRS and the Zacks Valuation Model to identify factors impacting equity valuations in 3 minutes or less Tim Nyland, CFA Managing Director Zacks Institutional Services January 26, 2015 STARBUCKS &
More informationTable of Contents. Company Overview
Table of Contents Company Overview Investing Philosophy Client Services Investment Process & Essential Elements Equity Strategies - Overview Opportunistic Composite Science & Technology Composite Client
More informationGrowth and Value Investing: A Complementary Approach
Growth and Value Investing: A Complementary Approach March 14, 2018 by Stephen Dover, Norman Boersma of Franklin Templeton Investments Growth and value investing are often seen as competing styles, with
More informationIssue 16 August We ll know we ve succeeded if surveys show that clients identify Denker Capital with those adjectives.
Issue 16 August 2015 SIM Global merges with SIM Unconstrained Capital Partners to form an independent boutique called Denker Capital in which Sanlam has 49% shareholding, Denker Capital 42% and 9% held
More information